Category: SPACs

Is the SEC considering guidance on SPAC projections?

Reuters is reporting—exclusively—that the SEC is contemplating issuing more guidance that would “rein in growth projections” made by listed SPACs and clarify when the PSLRA would be available to protect SPAC projections, “according to three people with knowledge of the discussions.”  According to Reuters, the SEC guidance “would escalate its crackdown on the […]

Past Event: Behind the Scenes of the 2021 IPO & SPAC Boom

Cooley, DFIN, PwC, Nasdaq and The Blueshirt Group hosted a two-part webinar series Behind the Scenes of the 2021 IPO & SPAC Boom on May 4 & 11, 2021. We heard the latest insights from leaders who have successfully completed recent IPOs or SPAC mergers and learned about the current capital raising […]

Past Event: 2020 TechGC SPAC Forum

SPACs and Direct Listings have emerged as a significant new liquidity path for high growth tech companies over the last several months. In this three-day virtual forum, we’ll discuss how to approach these liquidity events strategically including evaluating which structure to use, understanding economics / dilution, and how to execute […]

Past Event: SPACs – The Next Generation of IPOs or Just a Fad?

Driven by ongoing market pressures brought on by the COVID-19 pandemic, we have seen a surge of interest in special purpose acquisition (SPAC) transactions from companies across sectors. During this session, we heard from industry lawyers, exchange executives, and investment bankers on key considerations for navigating a SPAC merger, as […]

Past Event: Pacific Southwest Region SPAC / IPO Roundtable

Cooley partners Dave Peinsipp and Sean Clayton, Deloitte, Nasdaq and an investment banker well-versed in the IPO and SPAC processes to share insights on the next normal.

SPAC Transactions – Considerations for Target-Company CFOs

Although special-purpose acquisition companies (SPACs) have been used for decades as alternative investment vehicles, they have recently come into vogue as seasoned investors and management teams have turned to SPACs to mitigate the increased market volatility risk of traditional initial public offerings (IPOs). In fact, 2020 has been a record-breaking […]

A Couple of Quick Items Regarding IPO Alternatives

Here are two quick items regarding popular IPO alternatives, SPACs (special purpose acquisition corporations) and primary direct listings: SPACs.  In an interview on CNBC with Andrew Ross Sorkin on Thursday, SEC Chair Jay Clayton addressed the recent SPAC frenzy. (Very loosely, SPACs are companies with no real operations formed to […]

Past Event: Dealmakers Roundtable: SPACs!

On September 24th, 2020, Cooley partners Garth Osterman, Rama Padmanabhan, and Dave Peinsipp led a panel discussing the topics listed below. Topics include The recent acceleration of SPAC M&A activity Key timing considerations for a SPAC business combination The ways in which PIPEs and debt securities come into play Changing […]

Past Event: Cell & Gene Meeting on The Mesa

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This conference covers commercialization hurdles facing the cell and gene therapy sector as well as a wide range of topics […]

Past Event: Bay Area IPO Readiness Workshop

Cooley partner Dave Peinsipp, Deloitte and leaders from other organizations well-versed in the IPO, direct listing and SPAC processes shared their insights on the next normal. Topics include Current market conditions Regulatory considerations How to prepare for the IPO process Life as a public company Actionable insights from a CFO/controller […]